Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANXA2 | P07355 | 1/20 | 0.42 |
| ▸ | S100A10 | P60903 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 16/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932937 | 0.91 | RXFP1 (0.43) | ANXA2S100A10RXFP1KDM4ENPSR1 | |
| SCHEMBL6116273 | 0.91 | RXFP1 (0.44) | ANXA2S100A10RXFP1KDM4ECRHBP | |
| SCHEMBL934156 | 0.89 | RXFP1 (0.47) | ANXA2S100A10RXFP1KDM4ECRHBP | |
| SCHEMBL6115437 | 0.89 | RXFP1 (0.47) | ANXA2S100A10RXFP1KDM4ECRHBP | |
| SCHEMBL6115730 | 0.89 | RXFP1 (0.47) | ANXA2S100A10RXFP1KDM4ECRHBP | |
| SCHEMBL932829 | 0.89 | RXFP1 (0.47) | ANXA2S100A10RXFP1KDM4ECRHBP | |
| SCHEMBL6115476 | 0.89 | RXFP1 (0.46) | ANXA2S100A10RXFP1KDM4ECRHBP | |
| SCHEMBL933561 | 0.89 | ANXA2 (0.47) | ANXA2S100A10RXFP1KDM4ENPSR1 | |
| SCHEMBL933312 | 0.89 | ANXA2 (0.47) | ANXA2S100A10RXFP1KDM4ENPSR1 | |
| SCHEMBL933731 | 0.88 | RXFP1 (0.49) | ANXA2S100A10RXFP1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2451800-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | Vivalis (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | NAT1, POLM, PYGL | ANXA2 4355/4885S100A10 1052/4885RXFP1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.